In 2009, the Kidney Disease: Improving Global Outcomes (KDIGO) guidelines provided recommendations for induction therapy protocols, suggesting that recipients with low-immunological-risk conventionally receive non-lymphocyte-­depleting antibodies such as interleukin-2 receptor antagonists (IL-2RA) for induction. This evidence concerns the gene IL2RA and kidney disorder.